Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced.

中文翻译：

---

通过SGLT-2抑制作用预防2型糖尿病患者的主要不良心血管事件：肾脏的作用。

心血管结果试验（CVOT）已证明，使用SGLT-2抑制剂治疗的2型糖尿病（T2D）患者的主要不良心血管事件（MACE）显着降低。在大多数患者中，使用他汀类药物进行背景治疗时，情况仍然如此。值得注意的是，这种SGLT-2抑制剂的作用是独特的，因为与心血管保护的其他成分不同，MACE预防似乎不是一种类作用。在这里，我们对这四个关键CVOT进行荟萃分析，这些结果表明肾功能在确定MACE预防程度方面起着重要作用，在更严重的肾脏疾病（即传统方法的有效性较高的高危疾病）中获益增加他汀类药物的治疗方法减少了。